State of the Science Summit on Melanoma and Immuno-Oncology | Conference

Dr. Stein on Targeted Therapies for Melanoma

August 4th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.

Dr. Meehan on Importance of IHC Testing in Melanoma

July 31st 2017

Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.

Dr. Berman on Evolving Role of Surgery in Melanoma

July 31st 2017

Russell Berman, MD, division chief of Surgical Oncology at NYU Langone Medical Center, NYU Langone School of Medicine, shares insight on the evolving role of surgery in patients with melanoma.

Dr. Stein Discusses Skin-Related AEs With Melanoma Treatment

July 28th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Dr. Shapiro on Surgical Advancements in Field of Melanoma

July 28th 2017

Richard L. Shapiro, MD, associate professor, Department of Surgery, New York University Langone Medical Center, discusses recent advancements related to surgery in the field of melanoma.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.

Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma

July 27th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

Amid Molecular Diagnostic Advances, IHC Retains Significance in Melanoma

July 25th 2017

Shane A. Meehan, MD, discusses the continued importance of IHC testing in melanoma, even with the emergence of novel molecular assays.

Expert Shares Optimism on Surgical Advances in Melanoma

July 24th 2017

Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.

Surgical and Systemic Techniques Evolving for Melanoma Patients With Brain Mets

July 20th 2017

Douglas Kondziolka, MD, provides insight on some of the technical advancements in treating brain metastases in patients with melanoma.

Dermatologic Management of Melanoma Involves Observation of Skin AEs and New Primary Melanomas

July 14th 2017

Jennifer A. Stein, MD, PhD, discusses the skin-related adverse events for patients on treatment for melanoma, as well as the importance of identifying new primary melanomas.

Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

June 30th 2017

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Dr. Weber on Next Steps With Pembrolizumab as Melanoma Treatment

June 30th 2017

Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

Clinical Trials Are Essential in the Adjuvant Setting for High-Risk Melanoma

June 30th 2017

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

June 30th 2017

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Highlights Impressive Long-Term Activity With BRAF/MEK Combos in Melanoma

June 30th 2017

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.